Nexletol FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 27, 2021.
FDA Approved: Yes (First approved February 21, 2020)
Brand name: Nexletol
Generic name: bempedoic acid
Dosage form: Tablets
Company: Esperion Therapeutics, Inc.
Treatment for: High Cholesterol, Familial Heterozygous
Nexletol (bempedoic acid) is a first-in-class, adenosine triphosphate-citrate lyase (ACL) inhibitor for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-Cholesterol.
Development timeline for Nexletol
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.